Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR Total Liabilities
Everything the company owes to creditors and other parties.
Larimar Therapeutics, Inc.NASDAQ: LRMR
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 94.9% from a year ago
Total liabilities stood at $50.48M at the end of Q1 FY2026, up 94.9% from a year earlier and down 25.5% from the prior quarter. Over 3 fiscal years it compounded at +63.5% a year.
Context
- Total liabilities amounted to 24.2% of total assets at the end of Q1 FY2026, up 9.0 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +94.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 67.76M USD
- Year-over-year change
- +138.5%
- 4-year CAGR
- +47.7%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.76M | +138.5% |
| FY2024 | 2024-12-31 | 28.41M | +99.9% |
| FY2023 | 2023-12-31 | 14.22M | -8.3% |
| FY2022 | 2022-12-31 | 15.5M | +8.8% |
| FY2021 | 2021-12-31 | 14.25M | — |
Total Liabilities vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +94.9% is the 2nd highest of 11, against a peer median of +4.5%.
- Total liabilities amounts to 24.2% of total assets for LRMR, versus a peer median of 22.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $196.35M USD | +7.9% | -10.1% | 30.4% | |
| Mar 2026 | CHF 105.89M CHF | -8.9% | +86.2% | 77.1% | |
| Mar 2026 | $63.99M USD | +1.2% | -28.9% | 34.8% | |
| Mar 2026 | $61.44M USD | +67.7% | +44.9% | 23.9% | |
| Mar 2026 | $58.5M USD | +22.7% | +7.6% | 22.0% | |
| Mar 2026 | $58.36M USD | -1.5% | +6.9% | 22.2% | |
ENGNenGene Holdings Inc. | Apr 2026 | $52.36M USD | +33.0% | +126.6% | 17.0% |
| Mar 2026 | $51.64M USD | +242.0% | +36.5% | 15.4% | |
| Mar 2026 | $50.48M USD | +94.9% | +63.5% | 24.2% | |
| Mar 2026 | $32.89M USD | +0.2% | -27.8% | 11.9% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $18.86M USD | -49.8% | -52.8% | 7.5% |
| Peer median (excluding LRMR) | — | +4.5% | +7.3% | 22.1% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 70.1M | 26.83M | 26.75M | 33.22M | 85.41M |
| Short-term Investments | 0 | 91.6M | 60.04M | 150.24M | 51.44M |
| Net Receivables | 208K | 0 | 0 | 1.05M | 747K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 279K | 238K | 709K | 517K | 253K |
| Total Current Assets | 72.2M | 120.74M | 90.18M | 195.3M | 142.02M |
| Property, Plant & Equipment (Net) | 4.46M | 3.69M | 3.76M | 3.72M | 2.69M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.34M | 0 | 1.34M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 669K | 1.98M | 659K | 1.2M | 1.13M |
| Total Non-current Assets | 6.46M | 5.67M | 5.76M | 4.92M | 3.82M |
| Total Assets | 78.67M | 126.41M | 95.94M | 200.23M | 145.84M |
| Account Payables | 1.66M | 1.69M | 1.28M | 2.42M | 5.22M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.11M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 54.69M |
| Total Current Liabilities | 8.85M | 10.71M | 9.51M | 24.36M | 64.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.41M | 4.8M | 4.71M | 4.06M | 2.96M |
| Total Liabilities | 14.25M | 15.5M | 14.22M | 28.41M | 67.76M |
| Common Stock | 18K | 43K | 43K | 64K | 83K |
| Retained Earnings | (116.25M) | (151.61M) | (188.55M) | (269.16M) | (434.83M) |
| Accumulated OCI | (0) | (31K) | 81K | 148K | 54K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 64.41M | 110.9M | 81.72M | 171.81M | 78.09M |
| Total Debt | 6M | 5.41M | 5.55M | 5.12M | 4.07M |
| Net Debt | (64.1M) | (21.42M) | (21.2M) | (28.1M) | (81.35M) |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.